Cost-Utility Analysis of Infliximab and Adalimumab for Refractory Ulcerative Colitis

Cost Effectiveness and Resource Allocation - United Kingdom
doi 10.1186/1478-7547-7-20
Full Text
Abstract

Available in full text

Categories
Health Policy
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Cost-Minimization Analysis of Infliximab Versus Adalimumab in the Treatment of Crohn’s Disease and Ulcerative Colitis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Cost-Utility Analysis of 1-Year Treatment With Adalimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland

European Journal of Clinical Pharmacology
MedicinePharmacology
2016English

Long-Term Efficacy of Infliximab for Refractory Ulcerative Colitis: Results From a Single Center Experience

BMC Gastroenterology
MedicineGastroenterology
2014English

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

New England Journal of Medicine
Medicine
2005English

Cost-Effectiveness of Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis in the Netherlands

Biologics in Therapy
2012English

Comparative Efficacy and Safety of Golimumab, Infliximab and Adalimumab for the Treatment of Moderate to Severe Ulcerative Colitis: A Bayesian Indirect Treatment Comparison Meta-Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Adalimumab for Ulcerative Colitis: Results of a Brazilian Multicenter Observational Study

Arquivos de Gastroenterologia
Gastroenterology
2017English

Utility of Surveillance Colonoscopy in Ulcerative Colitis.

Gut
Gastroenterology
1994English

Letter: Dose Optimising Infliximab in Acute Severe Ulcerative Colitis

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy